In the last trading session, 1.56 million shares of the 4D Molecular Therapeutics Inc (NASDAQ:FDMT) were traded, and its beta was 2.78. Most recently the company’s share price was $5.32, and it changed around -$0.65 or -10.97% from the last close, which brings the market valuation of the company to $245.70M. FDMT currently trades at a discount to its 52-week high of $36.25, offering almost -581.39% off that amount. The share price’s 52-week low was $4.43, which indicates that the current value has risen by an impressive 16.73% since then. We note from 4D Molecular Therapeutics Inc’s average daily trading volume that its 10-day average is 1.06 million shares, with the 3-month average coming to 943.99K.
4D Molecular Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.82. If we narrow it down even further, the data shows that 1 out of 12 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 2 recommended FDMT as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. 4D Molecular Therapeutics Inc is expected to report earnings per share of -0.84 for the current quarter.
4D Molecular Therapeutics Inc (NASDAQ:FDMT) trade information
Instantly FDMT has showed a red trend with a performance of -10.97% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 6.91 on recent trading dayincreased the stock’s daily price by 23.01%. The company’s shares are currently down -4.58% year-to-date, but still down -10.37% over the last five days. On the other hand, 4D Molecular Therapeutics Inc (NASDAQ:FDMT) is -8.99% down in the 30-day period. We can see from the shorts that 7.67 million shares have been sold at a short interest cover period of 6.9 day(s).
The consensus price target as assigned by Wall Street analysts is $37.5, which translates to bulls needing to increase their stock price by 85.81% from its current value. Analyst projections state that FDMT is forecast to be at a low of $6 and a high of $40.
4D Molecular Therapeutics Inc (FDMT) estimates and forecasts
The year-over-year growth rate is expected to be -93.32%, down from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 2.28M in revenue for the current quarter. 3 analysts expect 4D Molecular Therapeutics Inc to make 176k in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were -19k and 28k respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 12,121.05%. Forecasts for the next quarter put sales growth at 528.57%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -46.35%. 4D Molecular Therapeutics Inc earnings are expected to increase by -12.47% in 2025, but the outlook is negative -15.10% per year for the next five years.
FDMT Dividends
4D Molecular Therapeutics Inc’s next quarterly earnings report is expected to be released in March.
4D Molecular Therapeutics Inc (NASDAQ:FDMT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 4.16% of 4D Molecular Therapeutics Inc shares, and 113.07% of them are in the hands of institutional investors. The stock currently has a share float of 117.97%. 4D Molecular Therapeutics Inc stock is held by 215.0 institutions, with RA CAPITAL MANAGEMENT, L.P. being the largest institutional investor. By 2024-06-30, it held 10.3471% of the shares, which is about 5.1 million shares worth $107.01 million.
BLACKROCK INC., with 9.9385% or 4.9 million shares worth $102.79 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Sep 30, 2024 . The former held 1.54 shares worth $8.17 million, making up 3.33% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 1.42 shares worth around $7.54 million, which represents about 3.07% of the total shares outstanding.
